Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.

PloS one - 1 Jan 2015

Laroche Audrey, Tran-Cong Kevin, Chaire Vanessa, Lagarde Pauline, Hostein Isabelle, Coindre Jean-Michel, Chibon Frederic, Neuville Agnes, Lesluyes Tom, Lucchesi Carlo, Italiano Antoine

Abstract excerpt

Nutlin inhibits TP53-MDM2 interaction and is under investigation in soft-tissue sarcomas (STS) and other malignancies. Molecular mechanisms of secondary resistance to nutlin in STS are unknown. We performed whole-transcriptome sequencing (RNA-seq) on three pretreatment and secondary resistant STS cell lines selected based on their high primary sensitivity to nutlin. Our data identified a subset of cancer gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clone Cells

Share to Imidazoles

Share to Ploidies

Share to Proto-Oncogene Proteins c-mdm2

Share to Pyrrolidines

Share to Sarcoma

Source

Open in PubMed Open full text

Identifiers

PMID: 26427052
DOI: 10.1371/journal.pone.0137794
PMCID: PMC4591276

Genes

STS
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.PMID 26427052Read ↗

Establishment and characterization of 18 Sarcoma Cell Lines: Unraveling the Molecular Mechanisms of Doxorubicin Resistance in Sarcoma Cell Lines.Semantic proximity Read ↗

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Semantic proximity Read ↗

Updates on altered signaling pathways in tumor drug resistanceSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization.Semantic proximity Read ↗

Drug resistance in recurrent and metastatic Ewing sarcomaSemantic proximity Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Multilevel Mechanisms of Cancer Drug Resistance.Semantic proximity Read ↗

Cancer Stem Cells as a Source of Drug Resistance in Bone SarcomasSemantic proximity Read ↗

Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.